Zai Lab Earnings Call Highlights Zoci Momentum and 2027 Catalysts
at www.tipranks.com (Sat, 14-Nov 8:34 PM)
Zai Lab spotlights 81.8% response rate for chemo-free zoci + atezolizumab regimen in first-line ES-SCLC
Market Chameleon (Fri, 23-Oct 7:05 AM)